Skip to contentB
Biofrontera Inc.
B
BFRIBiofrontera Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.10M$17.10Mderived+36.2% vs Q4 2024 Net Income$5.64M$5.64MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biofrontera Inc. · CIK 1858685 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$4,556,000N/M Operating Cash Flowderived-$2,376,000N/M Free Cash Flowderived-$2,375,000N/M Margins · derivedOperating margin26.6%+40.3 pt vs Q4 2024
Net margin33.0%+44.1 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 19, 2026 · 78 d after period end